Abstract
In Malaysia, co-circulation of CRF01_AE and subtype B has resulted in the emergence of the second generation derivative; CRF33_01B in approximately 20% of its HIV-1 infected individuals. Our objective was to identify possible biological advantages that CRF33_01B possesses over its progenitors. Biological and molecular comparisons of CRF33_01B against its parental subtypes clearly show that CRF33_01B replicated better in activated whole peripheral blood mononuclear cells (PBMCs) and CD4+ T-lymphocytes, but not monocyte-derived macrophages (MDMs). Also, its acquired fitness was greater than CRF01_AE but not subtype B. Moreover, CRF33_01B has higher rate of apoptotic cell death and syncytia induction compared to subtype B. These adaptive and survival abilities could have been acquired by CRF33_01B due to the incorporation of subtype B fragments into the gag-RT region of its full-length genome. Our studies confirm the previously held belief that HIV-1 strains may harbor enhanced biological fitness upon recombination. We therefore estimate a possible gradual replacement of the current predominance of CRF01_AE, as well as wider dissemination of CRF33_01B, together with the identification of other new CRF01_AE/B inter-subtype recombinants in Malaysia.
Keywords: HIV-1 CRF01_AE, HIV-1 subtype B, HIV-1 CRF33_01B, inter-subtype recombinant, biological fitness, Malaysia
Current HIV Research
Title: Evidence for Possible Biological Advantages of the Newly Emerging HIV-1 Circulating Recombinant Form from Malaysia - CRF33_01B in Comparison to its Progenitors _ CRF01_AE and Subtype B
Volume: 8 Issue: 3
Author(s): Katherine A. Lau, Bin Wang, Monica Miranda-Saksena, Ross Boadle, Adeeba Kamarulzaman, Kee-Peng Ng and Nitin K. Saksena
Affiliation:
Keywords: HIV-1 CRF01_AE, HIV-1 subtype B, HIV-1 CRF33_01B, inter-subtype recombinant, biological fitness, Malaysia
Abstract: In Malaysia, co-circulation of CRF01_AE and subtype B has resulted in the emergence of the second generation derivative; CRF33_01B in approximately 20% of its HIV-1 infected individuals. Our objective was to identify possible biological advantages that CRF33_01B possesses over its progenitors. Biological and molecular comparisons of CRF33_01B against its parental subtypes clearly show that CRF33_01B replicated better in activated whole peripheral blood mononuclear cells (PBMCs) and CD4+ T-lymphocytes, but not monocyte-derived macrophages (MDMs). Also, its acquired fitness was greater than CRF01_AE but not subtype B. Moreover, CRF33_01B has higher rate of apoptotic cell death and syncytia induction compared to subtype B. These adaptive and survival abilities could have been acquired by CRF33_01B due to the incorporation of subtype B fragments into the gag-RT region of its full-length genome. Our studies confirm the previously held belief that HIV-1 strains may harbor enhanced biological fitness upon recombination. We therefore estimate a possible gradual replacement of the current predominance of CRF01_AE, as well as wider dissemination of CRF33_01B, together with the identification of other new CRF01_AE/B inter-subtype recombinants in Malaysia.
Export Options
About this article
Cite this article as:
Lau Katherine A., Wang Bin, Miranda-Saksena Monica, Boadle Ross, Kamarulzaman Adeeba, Ng Kee-Peng and Saksena Nitin K., Evidence for Possible Biological Advantages of the Newly Emerging HIV-1 Circulating Recombinant Form from Malaysia - CRF33_01B in Comparison to its Progenitors _ CRF01_AE and Subtype B, Current HIV Research 2010; 8 (3) . https://dx.doi.org/10.2174/157016210791111151
DOI https://dx.doi.org/10.2174/157016210791111151 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases
Protein & Peptide Letters Nanocarriers for Effective Topical Delivery of Anti-Infectives
Current Nanoscience New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments
Current Pharmaceutical Biotechnology Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease
Cardiovascular & Hematological Disorders-Drug Targets Contemporary HIV Vaccines: Tissue Resident T-Cells and Strategies to Prevent Mucosal Infection
Current Topics in Medicinal Chemistry Subject Index To Volume 3
Current Neurovascular Research Colloidal Microgels in Drug Delivery Applications
Current Pharmaceutical Design How Often are Orphan Drugs Orphaned by the Thermochemical Community?
Current Medicinal Chemistry Ocular Toxocariasis: New Diagnostic and Therapeutic Perspectives
Recent Patents on Anti-Infective Drug Discovery Recent Evidence on the Role of Dietary PUFAs in Cancer Development and Prevention
Current Medicinal Chemistry Spinal Cord Injury Changes Cytokine Transport
CNS & Neurological Disorders - Drug Targets Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences Role of Caspases in Activation-Induced Cell Death of Neuroglia
Current Enzyme Inhibition High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
Current Cancer Drug Targets Cytokine Targeting in Osteoarthritis
Current Drug Targets The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery The Hypothalamic-Neurohypophyseal System: Current and Future Treatment of Vasopressin and Oxytocyn Related Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)